Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

 

→ About Us

 

→ Our papers

 

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
Update on the AMYPAD Prognostic and Natural History Study – Q2 2021
Update on the AMYPAD Prognostic and Natural History Study – Q2 2021 22 Jul 2021 In total, at the end of Q2 2021, AMYPAD PNHS had 1043 participants consented of which 909 have already undergone their amyloid PET scan......
AMYPAD at AAIC2021
AMYPAD at AAIC2021 21 Jul 2021 Seven AMYPAD abstracts have been accepted for the AAIC21 conference......
Recruitment update
Recruitment update 30 Jun 2021 AMYPAD PHNS: currently 1.034 participants recruited of which 886 have been scanned......
Recruitment status (as 13 July, 2021)
Recruitment status (as 13 July, 2021)